All medications have side effects, and GLP-1 receptor agonists are no exception. But what does the actual clinical trial data say about how common, how severe, and how manageable these side effects are?
Most Common Side Effects
Across all major GLP-1 trials, gastrointestinal side effects are the most common. Here is the data from the STEP 1 trial (semaglutide 2.4 mg) and SURMOUNT-1 trial (tirzepatide 15 mg):
From STEP 1 (Semaglutide, NEJM 2021):
| Side Effect | Semaglutide | Placebo |
|---|---|---|
| Nausea | 44.2% | 17.7% |
| Diarrhea | 30.6% | 16.3% |
| Vomiting | 24.8% | 6.2% |
| Constipation | 24.4% | 17.7% |
| Abdominal pain | 17.1% | 11.0% |
| Discontinuation due to GI events | 4.5% | 0.8% |
Source: Wilding et al., NEJM 2021. Nausea, diarrhea, vomiting, and constipation were typically mild to moderate and transient, occurring primarily during dose escalation.
From SURMOUNT-1 (Tirzepatide, NEJM 2022):
| Side Effect | Tirzepatide 15 mg | Placebo |
|---|---|---|
| Nausea | 42.5% | 17.2% |
| Diarrhea | 35.4% | 14.7% |
| Vomiting | 32.1% | 6.9% |
| Constipation | 24.0% | 13.1% |
| Dyspepsia (indigestion) | 15.7% | 6.1% |
| Discontinuation due to adverse events | 6.2% | 2.6% |
Source: Jastreboff et al., NEJM 2022.
Serious Side Effects
Serious adverse events were uncommon in both trials, but important to be aware of:
Gallbladder Disease
In SELECT, acute gallbladder disease occurred in 2.8% of semaglutide patients vs 1.8% on placebo. This is likely related to rapid weight loss rather than a direct drug effect, as rapid weight loss from any cause increases gallstone risk.
Pancreatitis
Rare. In STEP 1, pancreatitis occurred in 0.2% of semaglutide patients. In SURMOUNT-1, acute pancreatitis occurred in 0.4% of tirzepatide 10 mg/15 mg groups vs 0% placebo.
Retinopathy (Eye Complications)
In the SELECT trial, diabetic retinopathy-related adverse events occurred in 2.3% of semaglutide vs 1.8% placebo. This is consistent with the known effect of rapid glucose improvement temporarily worsening retinopathy (similar to what is seen with insulin initiation).
Are Side Effects Manageable?
Yes. Clinical experience shows that most side effects can be managed with the following strategies:
- Slow dose escalation: Following the recommended titration schedule significantly reduces GI side effects
- Dietary adjustments: Eating smaller, lower-fat meals; avoiding fried and spicy foods
- Hydration: Adequate fluid intake helps manage nausea and constipation
- Anti-nausea medications: Zofran (ondansetron) can be prescribed if needed
- Timing: Taking injections at bedtime can help sleep through initial nausea
In the clinical trials, the majority of participants who experienced nausea reported it was mild to moderate and resolved within days to weeks. Only 4-7% of participants discontinued due to GI side effects.
Long-Term Safety Profile
With over 5 years of clinical trial data now available for semaglutide and 3+ years for tirzepatide, the long-term safety profile is well-established. No new safety signals have emerged with extended use. The SELECT trial followed patients for an average of 39.8 months and showed a favorable benefit-risk profile.
References:
1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.